The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1449-1453

  Kaku, Tsunehisa ^a   Sonoda, Kenzo ^a   Kamura, Toshiharu ^a   Hirakawa, Toshio ^a   Sakai, Kunihiro ^a   Amada, Satoshi ^a   Ogawa, Shinji ^a   Kobayashi, Hiroaki ^a   Nakashima, Manabu ^b   Watanabe, Takeshi ^b   Nakano, Hitoo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 22 1 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVER VARIATION; PROGNOSIS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0032979473     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sonoda, K., Nakashima, M., Saito, T., Amada, S., Kamura, T., Nakano, H., and Watanabe, T. Establishment of a new human uterine cervical adenocarcinoma cell line, SiSo, and its reactivity to anti-cancer reagents. Int. J. Oncol., 6: 1099-1104, 1995.
2. Sonoda, K., Nakashima, M., Kaku, T., Kamura, T., Nakano, H., and Watanabe, T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer (Phila.), 77: 1501-1509, 1996.
3. Sonoda, K., Kaku, T., Kamura, T., Nakashima, M., Watanabe, T., and Nakano, H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin. Cancer Res., 4: 1517-1520, 1998.
4. Kaku, T., Kamura, T., Sakai, K., Amada, S., Kobayashi, H., Shigematsu, T., Saito, T., and Nakano, H. Early adenocarcinoma of the uterine cervix. Gynecol. Oncol., 65: 281-285, 1997.
5. Suster, S., Fisher, C., and Moran, C. A. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am. J. Surg. Pathol., 22: 863-872, 1998.
6. Ordóñe, N. G. Desmoplastic small round cell tumor. II: An ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am. J. Surg. Pathol., 22: 1314-1327, 1998.
7. Zheng, W., Khurana, R., Farahmand, S., Wang, Y., Zhang, Z-F., and Felix, J. C. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am. J. Surg. Pathol., 22: 1463-1473, 1998.
8. Leminen, A., Paavonen, J., Forss, M., Wahlstrom, T., and Vesterinen, E. Adenocarcinoma of the uterine cervix. Cancer (Phila.), 65: 53-59, 1990.
9. Angel, C., Du Beshter, B., and Lin, J. Y. Clinical presentation and management of stage I cervical adenocarcinoma. Gynecol. Oncol., 44: 71-77, 1992.
10. Yoshida, K., Okuda, H., Hayashi, Y., Nakagiri, Y., and Sekiba, K. A. Clinicopathological study on adenocarcinoma of the uterine cervix. Acta Obstet. Gynaecol. Jpn., 43: 261-265, 1991.
11. Tamini, H. K., and Figge, D. C. Adenocarcinoma of the uterine cervix. Gynecol. Oncol., 13: 335-344, 1982.
12. Hopkins, M. P., and Morley, G. W. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet. Gynecol., 77: 912-917, 1991.
13. Duk, J. M., Aalders, J. G., Fleuren, G. J., Krans, M., and de Bruijn, H. W. A. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet. Gynecol., 73: 661-668, 1989.
14. Leminen, A. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol. Oncol., 39: 358-363, 1990.
15. Duk, J. M., de Bruijn, H. W. A., Groenier, K. H., Fleuren, G. J., and Aalders, J. G. Adenocarcinoma of the uterine cervix, prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer (Phila.), 65: 1830-1837, 1990.
16. Lehtovirta, P., Vinikka, L., and Ylikorkala, O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol. Oncol., 37: 276-278, 1990.
17. Fujii, S., Konishi, I., Nanbu, Y., Nonogaki, H., Kobayashi, F., Sagawa, N., Mori, T, and Endo, K. Analysis of the levels of CA 125, carcinoembryonic antigen, and CA 19-9 in the cervical mucus for a detection of cervical adenocarcinoma. Cancer (Phila.), 62: 541-547, 1988.
18. Åvall-Lundqvist, E. H., Sjövall, K., Nilsson, B. R., and Eneroth, P. H. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur. J. Cancer, 28: 1695-1702, 1992.
19. Tomás, C., Risteli, J., Risteli, L., Vuori, J., and Kauppila, A. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma. Obstet. Gynecol., 77: 566-572, 1991.
20. Nanbu, Y., Fujii, S., Konishi, I., Nonogaki, H., and Mori, T. Immunohistochemical localizations of CA 125, carcinoembryonic antigen, and CA 19-9 in normal and neoplastic glandular cells of the uterine cervix. Cancer (Phila.), 62: 2580-2588, 1988.
21. Kjorstad, K. E., and Ørjasaeter, H. The prognostic significance of carcinoembryonic antigen determinations in patients with adenocarcinoma of the cervix. Gynecol. Oncol., 19: 284-289, 1984.
22. Schwartz, P. E., Chambers, S. K., Chambers, J. T., Gutmann, J., Katopodis, N., and Foemmel, R. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer (Phila.), 60: 353-361, 1987.
23. Kihana, T., Tsuda, H., Teshima, S., Nomoto, K., Tsugane, S., Sonoda, T, Matsuura, S., and Hirohashi, S. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer (Phila.), 73: 148-153, 1994.
24. WAF1/CIP1 in adenocarcinoma of the uterine cervix. A possible immunohistochemical marker of a favorable prognosis. Cancer (Phila.), 82: 2409-2417, 1998.